Q VYJUVEK global revenue and $846.7 million since launchEnrollment complete in KB803 (corneal abrasions in DEB patients) ...

Corcept Therapeutics Inc. (NASDAQ: CORT) is one of the 10 best biotech stocks with highest upside potential.

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Andrew Hillman Grant for Biotech Introduces National Opportunity for Undergraduate Talent to Explore the Future of ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for ...

In Salt Lake City, biotech founders new and seasoned reflect on ways to ride out the industry’s challenges, such as sending ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...

A cross-section of biotech leaders is launching the American Biotech Innovation Alliance (ABIA) with the goal of uniting ...

By Marleen Kaesebier BASEL, Switzerland, May 5 (Reuters) - Switzerland's biotech industry shifted toward private financing in 2025 as funding from capital markets remained difficult to obtain and ...